ReviewInternational journal of reproductive biomedicine2025
Unveiling the molecular nexus: Long non-coding RNAs, RNA-binding proteins, and DNA damage in ovarian ischemia-reperfusion injury: A narrative review.
Review in International journal of reproductive biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian ischemia-reperfusion injury (IRI) is a pathology that entails the interruption of blood supply to the ovary and subsequent restoration of flow, causing tissue damage and dysfunction. Therefore, the identification of cisternal components, long non-coding RNAs (lncRNAs), and RNA-binding proteins (RBPs), as well as their roles in the DNA damage response (DDR), is critical in understanding the underlying molecular mechanisms and finding potential therapeutic targets. Therefore, the expression profile of lncRNA and the regulation of DDR in various cellular processes can be controlled through interactions with RBPs. As scaffolds, guides or decoys regulating RNA processes, mediating DNA repair, and other cellular responses to genotoxic stress, lncRNAs play their roles. Alterations of lncRNA-RBP interactions have been involved in multiple diseases, including ovarian IRI, which prompts their further assessment as therapeutic targets. Abnormal RBPs will lead to the disruption of RNA homeostasis, a decline in DNA repair, and the exacerbation of the IRI-mediated tissue damage in the ovaries. These pathways are involved in cell cycle regulation, DNA repair, and apoptosis regulation in ovarian IRI, and manipulation of these pathways by lncRNAs and RBPs identified here may contribute to disease progression and/or serve as potential therapeutic targets. Studying these molecular processes promises almost targeted therapeutic approaches to individualized treatment. Future studies should try to understand the differential contribution of particular lncRNAs and RBPs, as well as DDR pathways involved in ovarian IRI, to provide better prognostic estimates and ameliorate ovarian function in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.